ReviewReviews in endocrine & metabolic disorders2021
PRRT: identikit of the perfect patient.
Review in Reviews in endocrine & metabolic disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety ofFrontiers in oncology · 2022Pooled it
- Can clinicians predict individual patient outcomes in neuroendocrine tumors treated with [177Lu]Lu-DOTATATE?The oncologist · 2026Article
- Normal organ [European journal of nuclear medicine and molecular imaging · 2026Article
- The Role of Radioligand Therapy in Gastroenteropancreatic Neuroendocrine Tumors: An Italian Expert Opinion.Advances in therapy · 2025Review
- Tumor Growth Rate in Neuroendocrine Neoplasms: An Additional Tool for Treatment Strategies?Medicina (Kaunas, Lithuania) · 2025Review
- Sequencing Choices and Real-World Clinical Management in Advanced Grade 2/3 GEP-NET Treatment: The Emerging Role of PRRT.Cancers · 2025Review
- Organ-specific response to [Endocrine · 2025Article
- Role ofFrontiers in medicine · 2025Article
- Prediction of lesion-based response to PRRT using baseline somatostatin receptor PET.Frontiers in medicine · 2025Article
- Non-[Pharmaceuticals (Basel, Switzerland) · 2024Review
- Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study.EJNMMI research · 2024Article
- Retrospective evaluation of the predictive value of tumour burden at baseline [EJNMMI reports · 2024Article
- Interim Analysis of a Prospective Validation of 2 Blood-Based Genomic Assessments (PPQ and NETest) to Determine the Clinical Efficacy ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Article
- Review
- Treatment efficacy in a metastatic small intestinal neuroendocrine tumour grade 2 cohort.Endocrine-related cancer · 2023Article
- Radioligand therapy (RLT) as neoadjuvant treatment for inoperable pancreatic neuroendocrine tumors: a literature review.Endocrine · 2022Review
- Glucose Metabolism Modification Induced by Radioligand Therapy with [Pharmaceutics · 2022Article
- Article
- Potential value of pre- and post-therapy [68Ga]Ga-DOTA-TATE PET/CT in the prognosis of response to PRRT in disseminated neuroendocrine tumors.Frontiers in endocrinology · 2022Article
- Prophylactic Peripheral Blood Stem Cell Collection in Patients with Extensive Bone-Marrow Infiltration of Neuroendocrine Tumours Prior to Peptide Receptor Radionuclide Therapy withPharmaceuticals (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Peptide receptor radionuclide therapy (PRRT) has been strengthened since the publication of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated, and no optimal sequence has yet been standardized. Possible criteria to predict the response to PRRT in neuroendocrine tumors (NET) have been proposed. The aim of this review is to define the perfect identity of the eligible patient who can mostly benefit from this therapy. Possible predictive criteria which have been analysed were: primary tumor site, grading, tumor burden, FDG PET and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.